Pituitary adenylate cyclase-activating polypeptide はエクリン汗腺の汗分泌を促進する by 佐々木 駿
For Peer Review
 
 
 
 
 
 
Pituitary adenylate cyclase-activating polypeptide promotes 
eccrine gland sweat secretion 
 
 
Journal: British Journal of Dermatology 
Manuscript ID BJD-2016-0737.R1 
Manuscript Type: Original Article 
Date Submitted by the Author: 20-Jun-2016 
Complete List of Authors: Sasaki, Shun; Showa Daigaku, Dermatology 
Watanabe, Jun; Showa Daigaku, Centre for Biochemistry 
Ohtaki, Hirokazu; Showa Daigaku, Department of Anatomy 
Matsumoto, Minako; Showa Daigaku, Biochemistry 
Murai, Norimitsu; Showa Daigaku, Physiology 
Nakamachi, Tomoya; Toyama Daigaku, Laboratory of Regulatory Biology 
Hannibal, Jens; University of Copenhagen, Clinical Biochemistry 
Fahrenkrug, Jan; University of Copenhagen, Clinical Biochemistry 
Hashimoto, Hitoshi; Osaka University, Laboratory of Molecular 
Neuropharmacology,Graduate School of Pharmaceutical Sciences; Osaka 
University, iPS Cell-based Research Project on Brain Neuropharmacology 
and Toxicology, Graduate School of Pharmaceutical Sciences; Osaka 
University, Kanazawa University, Hamamatsu University School of 
Medicine, Chiba University and University of Fukui, Molecular Research 
Center for Children’s Mental Development, United Graduate School of Child 
Development 
Watanabe,  Hideaki; Showa Daigaku, Dermatology 
Sueki, Hirohiko; Showa Daigaku, Dermatology 
Honda, Kazuho; Showa Daigaku, Anatomy 
Miyazaki, Akira; Showa Daigaku,  Biochemistry 
Shioda, Seiji; Hoshi Yakka Daigaku, Neuropeptide Drug Discovery 
Keywords: 
Pituitary adenylate cyclase-activating polypeptide, eccrine sweat gland, 
sweat secretion, PAC1 receptor 
  
 
 
British Journal of Dermatology
For Peer Review
Pituitary adenylate cyclase-activating polypeptide 
promotes eccrine gland sweat secretion  
 
Running head: PACAP promotes eccrine gland sweat secretion  
 
S. Sasaki,1, 2 J. Watanabe,3 H. Ohtaki,4 M. Matsumoto,1 N. Murai,5 T. 
Nakamachi,6 J. Hannibal7, J. Fahrenkrug7, H. Hashimoto,8, 9, 10 H. Watanabe2, 
H. Sueki,2 K. Honda,4 A. Miyazaki,1 and S. Shioda11  
 
Department of 
1
Biochemistry, 
2
Dermatology, 
4
Anatomy and 
5
Physiology, Showa 
University School of Medicine, Tokyo, Japan 
3
Center for Biotechnology, Showa University, Tokyo, Japan  
6
Laboratory of Regulatory Biology, Graduate School of Science and Engineering, 
University of Toyama, Toyama, Japan  
7
Department of Clinical Biochemistry, Faculty of Health and Medical Science, 
Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.  
Page 1 of 53 British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8
Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical 
Sciences, Osaka University, Osaka, Japan.
 
 
9
iPS Cell-based Research Project on Brain Neuropharmacology and Toxicology, 
Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan  
10
Molecular Research Center for Children’s Mental Development, United Graduate 
School of Child Development, Osaka University, Kanazawa University, Hamamatsu 
University School of Medicine, Chiba University and University of Fukui, Osaka, Japan 
11
Department of Neuropeptide Drug Discovery, Hoshi University School of Pharmacy 
and Pharmaceutical Sciences, Tokyo, Japan  
 
Correspondence:  
Seiji Shioda 
Department of Neuropeptide Drug Discovery, Hoshi University School of Pharmacy 
and Pharmaceutical Sciences  
Address: Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan  
Tel: +81- 3-5498-5853 
Page 2 of 53British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Fax: +81- 3-5498-5853  
E-mail: shioda@hoshi.ac.jp 
 
Funding: This study was supported in part by JSPS KAKENHI Grant No. 26293020, 
26670122, 25861289, 23249079, 15H01288 and 15K15670; JSPS Program for 
Advancing Strategic International Networks to Accelerate the Circulation of Talented 
Researchers, Grant No. S2603 (HH).  
 
Conflict of interest: None of the authors have commercial associations that might pose 
a conflict of interest in connection with the submitted article.  
 
Page 3 of 53 British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
What’s already known about this topic?  
Pituitary adenylate cyclase-activating polypeptide (PACAP) exhibits pleiotropic 
functions in the central nervous system, including neurotransmission, neuroprotection, 
and vasodilatation. In the skin, PACAP and its receptors were reported to be important 
mediators of cutaneous vasoregulation and neurogenic inflammation; however, their 
involvement in eccrine sweat secretion has not been examined.  
 
What does this study add?  
Subcutaneous administration of PACAP into the mouse footpad was found to promote 
sweat secretion. This effect was mediated through PAC1R expressed in the secretory 
cells of eccrine sweat glands. Most PAC1R-immunopositivity was observed in these 
secretory cells. Immunoreactivity to PACAP was observed in nerve fibres around sweat 
glands and in the secretory cells. These findings suggest that PACAP may provide new 
therapeutic options to modulate the sweating response.  
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Summary  
Background Sweat secretion is the major function of eccrine sweat glands; when this 
process is disturbed (paridrosis), serious skin problems can arise. To elucidate causes 
of paridrosis, an improved understanding of the regulation, mechanisms and factors 
underlying sweat production is required. Pituitary adenylate cyclase-activating 
polypeptide (PACAP) exhibits pleiotropic functions that are mediated via its receptors 
(PAC1R, VPAC1R and VPAC2R). Although some studies suggested a role for PACAP 
in the skin and several exocrine glands, the effects of PACAP on the process of eccrine 
sweat secretion have not been examined.  
Objectives To investigate the effect of PACAP on eccrine sweat secretion.  
Methods RT-PCR and immunostaining were used to determine the expression and 
localization of PACAP and its receptors in mouse and human eccrine sweat glands. We 
subcutaneously injected PACAP into the footpads of mice and used the starch iodine 
test to visualize sweat-secreting glands.  
Results Immunostaining showed PACAP and PAC1R expression by secretory cells 
from mouse and human sweat glands. PACAP immunoreactivity was also localized in 
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nerve fibres around eccrine sweat glands. PACAP significantly promoted sweat 
secretion at the injection site, and this could be blocked by the PAC1R-antagonist 
PACAP6-38. Vasoactive intestinal peptide (VIP), an agonist of VPAC1R and 
VPAC2R, failed to induce sweat secretion. 
Conclusions This is the first report demonstrating that PACAP may play a crucial role 
in sweat secretion via its action on PAC1R located in eccrine sweat glands. The 
mechanisms underlying the role of PACAP in sweat secretion may provide new 
therapeutic options to combat sweating disorders.  
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Sweat secretion is the main function of eccrine sweat glands in human beings. The 
autonomic nervous system triggers sweat secretion in response to increased body 
temperature or stress.
1
 Paridrosis, including hyperhidrosis and anhidrosis, can give rise 
to serious skin conditions such as pruritis and erythema, causing emotional distress and 
significantly reducing quality of life.
2,3
 Possible health-related issues associated with 
these disorders include the need for medication, as well as underlying diseases and 
mental stress.
4
 Although paridrosis is generally considered to be a nervous system 
abnormality, its cause is often unknown.  
   While there are no clearly established treatment regimens for hyperhidrosis and 
anhidrosis, currently proposed treatments have limitations because their effects may be 
temporary, or they are indicated only in severe cases, with no guarantee of success.
5-10
 
In order to develop new treatments, further understanding of the regulation of sweating, 
and elucidation of its underlying mechanisms are required.  
  Pituitary adenylate cyclase-activating polypeptide (PACAP), originally isolated from 
ovine hypothalamus,
11
 is a peptide that functions as a neurotransmitter, neuromodulator, 
neurotrophic factor,
12,13
 neuroprotectant,
14-16
 and vasodilator,
17,18
 in the central and 
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peripheral nervous systems. PACAP is a member of the VIP/secretin/glucagon family 
of peptides
12
, with the N-terminal portion of mammalian PACAP showing 68% 
homology with porcine VIP.
11
 The PACAP-specific receptor (PAC1R) binds PACAP 
with a thousand times higher affinity than it binds to VIP. The VPAC1 and VPAC2 
receptors (VPAC1R, VPAC2R) bind VIP and PACAP with similar affinities.
19
 While 
PACAP’s role as a neurotransmitter in the central and peripheral nervous systems is 
relatively well-described, its role and distribution in the sweat glands are less well 
elucidated. A recent study reported that PACAP and PAC1R mRNA are expressed in 
mouse skin, and that PAC1R immunoreactivity was observed in the basal, polygonal 
and granular layers of the epidermis.
20
 In addition, PACAP was reported to be 
localized in nerve fibres around exocrine tissue such as the mammary 
21
 and lacrimal 
glands.
22
 Although PACAP is reported to be involved in inflammation of the skin,
20
 its 
effects on sweat production by eccrine glands have not been elucidated. One study did 
report an observed ultracytochemical localization of adenylate cyclase after the 
stimulation of human sweat glands with PACAP.
23
 However, it is not known if PACAP 
and its receptors (PAC1R, VPAC1R and VPAC2R) are present in eccrine sweat glands.  
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   This study was undertaken to investigate PACAP’s role in sweat secretion and to 
define the localization of PACAP and PACAP receptors in mouse and human eccrine 
sweat glands. We demonstrate that PACAP and PAC1R are present in these sweat 
glands, and further show the effects of PACAP injection on the in vivo modulation of 
sweat in mouse skin.  
 
Material and methods  
Experimental animals  
Wild-type C57BL/6J mice were purchased from Sankyo Lab Service Corporation 
(Tokyo, Japan). In all experiments, adult male mice (11 to 19 weeks old) were used. 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee of Showa University (# 54022 and # 55003).  
 
Experimental human samples 
Human skin samples were obtained from patients (2 males and 4 females; average age, 
45.3 ± 14 years,) undergoing surgical therapy to extirpate benign tumors from the 
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plantar region of the foot. All patients provided their informed consent to participate in 
the study. Normal skin from the outer boundary of the extirpated tissue was used in 
experiments. This clinical study was approved by the Ethics Committee (EC) of Showa 
University School of Medicine (Approval No. 2014-1670). Human brain total RNA 
was purchased from Clontech Laboratories, Inc. (Cat.: 636530, Mountain View, CA).  
 
Total RNA extraction and RT-PCR  
Total RNA extraction and RT-PCR were performed as described previously.
24-27
 Tissue 
samples from dome-shaped footpads of mice and from human plantar skin were 
obtained for RNA extraction. Following removal of the epidermis, dermis rich-tissues 
were used for mouse samples. Whole planter skin were used for human samples. 
Liquid nitrogen-frozen tissues were individually ground to a very fine powder using 
mortar and a pestle. The powdered samples were transferred to 2 ml Eppendorf 
microtubes and stored in aliquots at –80°C until use. Total RNA was extracted from 
sample powder using the QIAGEN RNeasy Mini Kit (QIAGEN, Maryland, MD). 
Samples were first treated with RNase-free DNase (Stratagene, Agilent Technologies, 
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La Jolla, CA), and cDNA then synthesized in a 20 µl reaction mixture with an 
AffinityScript QPCR cDNA Synthesis Kit (Stratagene, Agilent Technologies, La Jolla, 
CA) according to the manufacturer’s protocol. RT-PCR was performed on the reaction 
mixture containing cDNA, each primer set, and Emerald Amp PCR Master Mix 
(TaKaRa Shuzo, Shiga, Japan), using a S1000 thermal cycler (BIO RAD, Hercules, 
CA). Primer sequences and PCR conditions are given in Table 1. Electrophoresis was 
then performed for 25 minutes at 100V in 1% TAE buffer. Gels were stained with 
ethidium bromide and bands visualized using a ChemiDoc XRS+ imaging system (BIO 
RAD).  
 
Immunohistochemistry 
   Detailed methods for immunostaining are provided in the supplementary 
materials and methods. Briefly, mouse and human skin samples were fixed with 4% 
paraformaldehyde (PFA) in 50 mM phosphate buffer (pH 7.2) or Zamboni’s solution 
(2% PFA and 15% picric acid in 0.1 M phosphate buffer pH 7.2) for PACAP 
staining.
28,29
 Frozen sections were cut with a microtome at a thickness of 5 µm. Rabbit 
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anti-PAC1R polyclonal antibody (1:400; created by our laboratory), mouse 
anti-Smooth Muscle Actin (SMA) monoclonal antibody (1:400; R & D SYSTEMS, 
Cat.: MAB1420, Minneapolis, MN), mouse anti-PACAP monoclonal antibody (code 
Mab JHH1, diluted 1:5; created by Jens Hannibal, Department of Clinical Biochemistry, 
Bispebjerg Hospital, University of Copenhagen, Denmark)
28,29
 and rabbit 
anti-neurofilament 200 (NF-200) polyclonal antibody (1:5000; SIGMA, Pro.: N 4142, 
Saint Louis, MO) were used as primary antibodies. As a negative control, some 
sections were stained without the primary antibody. For single staining, biotinylated 
goat anti-rabbit IgG (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
followed by reaction with an avidin-biotin complex solution (Vector, Burlingame, CA, 
USA) and then diaminobenzidine (Vector) as a chromogen were used for visualization. 
Detection was carried out using an AX70 microscope (Olympus, Tokyo, Japan). For 
double immunostaining, Alexa 488 and 546 anti-rabbit IgG antibody and Alexa Fluor 
488 and 546 anti-mouse IgG (1:400; Life Technologies, Carlsbad, CA) were used for 
visualization, then counterstained with 4,6-Diamidine-2-phenylindole dihydrochloride 
(DAPI, 1:10000; Roche, Mannheim, Germany) to identify cell nuclei. ApoTome (Zeiss, 
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Oberkochen, Germany) (Figs 2g-i) and Nikon A1 confocal microscopy (Nikon, Tokyo, 
Japan) (Figs 2a-c, 3b-d and f-h) were used for acquiring images. The specificity of 
PACAP antibody in nerve fibres was confirmed in mouse brain hypothalamic tissue 
(Fig. S1; see Supporting Information).  
 
Evaluation of sweat secretion by the starch iodine test  
Functional sweat-secreting glands were visualized by the alternative Minor 
starch-iodine test as described previously.
24-27,30,31
 Adult C57BL/6J mice (n=10) were 
anesthetized with 10 µl/g B.W. pentobarbital (Kyoritsu, Tokyo, Japan), and their paws 
coated with 10% povidone-iodine solution (Hakuzo Medical, Osaka, Japan). After 
drying, paws were coated with 50% corn starch solution (Wako Pure Chemical 
Industries, Osaka, Japan) in castor oil (Nichi-Iko Pharmaceutical Co., Ltd., Toyama, 
Japan). PACAP (Peptide Institute, Osaka, Japan) in the amount of 0 mol, 0.5 fmol, 50 
fmol or 5 pmol in 5 µl saline containing 0.1% BSA was subcutaneously injected into 
the dermis in the center of the footpad with a 27G needle (HAMILTON, Reno, NV) 
attached to a 25 µl glass syringe (HAMILTON) as shown in the schematic protocols in 
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Fig. 4a,b. In a second series of experiments, vehicle or 50 pmol PACAP6-38 was 
injected 10 minutes before 5 pmol PACAP or VIP administration (Fig. 5a). Images 
were captured in which sweat secretion, shown in the form of black dots, was later 
quantified.  
 
Statistical analysis 
Data are presented as the means ± SEM. The Tukey-Kramer HSD test was used to 
assess the statistical significance of independent experiments. Values of P<0.05 were 
considered to indicate statistical significance.  
 
Results 
 
PACAP, VIP, PAC1R, VPAC1R and VPAC2R are expressed in the mouse 
dermis  
mRNA transcripts specific for PACAP, VIP, PAC1R, VPAC1R and VPAC2R were 
detected by RT-PCR in the footpad (Fig. 1). Strong expression of VIP and PAC1R 
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mRNA was found in the tissue extracts, while PACAP, VPAC1R and VPAC2R mRNA 
expression levels were moderate.  
 
PACAP and PAC1R are expressed in the mouse footpad, with most 
PACAP-positive cells observed in nerve fibres. PAC1R-positive cells were 
observed to be secretory cells in mouse sweat glands  
   Following immunohistochemical staining, strong PACAP immunoreactivity was 
observed in eccrine sweat gland secretory cells (Fig. 2b). In addition to secretory cells, 
PACAP-immunoreactivity was observed in nerve fibres around the mouse sweat 
glands (Fig 2b arrows). Double-immunostaining with PACAP (red) and 
neurofilament-200 (NF-200, green) showed the colocalization of PACAP and NF-200 
in nerve fibres around the mouse sweat glands (Figs 2a-c).  
   We next investigated the degree of PAC1 receptor expression in mouse skin. 
PAC1R immunoreactivity was found in sweat glands and in the basal, polygonal and 
granular layers of the epidermis. PAC1R immunoreactivity was also detected in the 
stratum corneum; however as it was also observed in the negative control, it was 
Page 15 of 53 British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
considered to be non-specific (Fig 2d). Strong PAC1R immunoreactivity was observed 
in the secretory cells of eccrine sweat glands (Figs 2e and f). This was confirmed by 
double-immunostaining with PAC1R (red) and smooth muscle actin (SMA, green), 
which showed that most PAC1R-positive cells were secretory cells. SMA and PAC1R 
immunoreactivity did not overlap, suggesting PAC1R was not expressed in 
myoepithelial cells (Figs 2g, h and i). The negative control (primary antibody-free) did 
not show any signal (data not shown).  
 
PACAP and PAC1R are expressed in the human plantar dermis with 
similar localization to that in the mouse footpad  
RT-PCR analyses were performed to verify differences in human PACAP and PAC1R 
mRNA expression in the dermis of the plantar surface of the foot compared with brain 
tissue. PACAP mRNA expression levels were significantly lower in the plantar dermis 
compared to brain tissue (Fig. 3a). On the other hand, similar levels of PAC1R 
expression were observed in the plantar dermis and brain. PACAP and PAC1R 
expression levels were not significantly different between two samples of human 
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dermis.  
   Immunohistochemistry studies of human plantar tissue showed that 
PACAP-containing nerve fibres around sweat glands, as found in the mouse (Fig. 3 
b-d). Immunohistochemical staining showed a similar pattern of PACAP and PAC1R 
localization in human plantar skin as in the mouse footpad. Strong PAC1R 
immunoreactivity was observed in the secretory cells of eccrine sweat glands and also 
in the sudoriferous duct (Fig. 3e). Human sweat gland sections showed 
double-immunostaining with PAC1R (red) and SMA (green), with most 
PAC1R-positive cells observed to be secretory cells. This result suggests that the roles 
of PACAP in sweat secretion in humans and rodents could be similar. Again, the 
negative control (primary antibody-free) did not show any signal (data not shown).  
  
PACAP injection into the footpad caused a significant increase in the 
number of active sweat glands  
Based on these anatomical findings, we examined the effects of PACAP injection on 
the modulation of sweat secretion in the mouse footpad. PACAP in the amount of 0 
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mol (vehicle), 0.5 fmol, 50 fmol or 5 pmol was subcutaneously injected into the 
footpad of anesthetized adult mice. After 120 minutes, mice injected with 5 pmol 
PACAP exhibited a significantly higher number of visibly functional sweat glands in 
the footpad (arrows, Fig. 4c) compared with mice in the vehicle group and groups 
injected with lower concentrations of PACAP. The administration of PACAP at the 
amount of 0.5 fmol and 50 fmol did not result in a statistically significant increase in 
the number of active sweat glands, but a tendency towards a dose-dependent response 
was observed (Fig. 4d).  
 
Effect of PACAP on sweat secretion shows a slow time course and local 
site reaction 
When pilocarpine (a non-selective muscarinic receptor agonist) was injected into the 
footpads of mice, sweat gland secretion was observed within 5 minutes and remained 
constant thereafter. (Fig. S2; see Supporting Information). In contrast, a response to 
PACAP could only be observed 120 minutes after the injection. To examine whether 
the effect of PACAP was influenced by the use of anesthesia or not, PACAP or vehicle 
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was injected into the mouse footpad 60 minutes after anesthesia as shown in Fig. 4b. 
While 5 pmol PACAP did not increase sweat secretion 60 minutes after injection (120 
minutes after anesthesia), a significant difference in sweat secretion was observed 90 
minutes after the PACAP injection (150 minutes after anesthesia). This result suggests 
that PACAP could modulate sweat secretion over a slow time course. To investigate 
whether PACAP acts in a local or systemic manner, we compared sweat secretion on 
the ipsi- and contralateral side to PACAP administration. A significant increase in the 
number of active sweat glands occurred only in the footpad injected with PACAP (Fig. 
4f), suggesting that PACAP reacts locally with receptors in the mouse footpad to cause 
increased sweat secretion. Unexpectedly, PACAP-null mice showed normal sweat 
secretion after pilocarpine administration (Fig. S2; see Supporting Information). These 
results suggest that PACAP might play a role in sweat secretion via an acetylcholine 
receptor-independent pathway.  
 
Local administration of PACAP promotes sweat secretion via an action on 
PAC1R  
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We next investigated which receptor type is involved in mediating the effects of 
PACAP on sweat secretion by employing a PAC1R-antagonist (PACAP6-38) and 
VPAC1R- and VPAC2R-agonist (VIP) as indicated in Fig. 5a. Administration of 
PACAP (5 pmol) to the footpad caused a significant increase in the number of active 
sweat glands 120 minutes and 150 minutes after injection, which was negated by the 
co-administration of PACAP6-38 (Figs 5b and c). When employed in a similar manner, 
VIP (5 pmol) did not promote sweat secretion to a significant extent (Figs. 5b and c). 
These results indicate that the local administration of PACAP promotes sweat secretion 
in a manner that is mediated via PAC1R expressed in sweat glands.  
 
Discussion  
To our knowledge, this is the first report showing that PACAP promotes sweat secretion 
from eccrine sweat glands. In one recent paper, PAC1R was reported to be expressed in 
the basal, polygonal and granular layers of the epidermis, 
20
 while an important role of 
PACAP in the skin was suggested by the significantly higher concentrations of PACAP 
peptide in the skin of psoriasis patients compared to normal skin.
32
 Another report 
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showed that intravenously injected PACAP induced, in a dose-dependent manner, 
vascular responses such as flushing, erythema and edema in human skin.
33
 PACAP and 
its receptors may thus be important mediators of cutaneous vasoregulation and 
neurogenic inflammation under physiological and pathophysiological conditions. 
Although several reports have shown that PACAP could be involved in inflammation 
of the skin, no reports have described the expression and effects of PACAP and PAC1R 
in sweat glands. To this end, we confirm here that PACAP and its receptors are 
expressed in mouse and human skin, and that PACAP administration induces 
significant sweat secretion via its actions on PAC1R. PAC1R-positive cells were 
mostly secretory cells in mouse and human eccrine sweat glands. These studies thus 
establish an important role for PACAP in sweat production, and may serve to enhance 
our understanding of the pathophysiological mechanisms underlying hyperhidrosis and 
anhidrosis.  
   In our investigation of the effects of PACAP on sweat secretion, wild-type mice that 
received a subcutaneous injection of PACAP showed a dose-dependent local activation 
of sweat glands. It is well known that acetylcholine induces sweating via the 
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stimulation of muscarinic receptors. When pilocarpine was injected into the footpads of 
mice, functional sweat gland secretion was observed within 5 minutes (Fig. S2; see 
Supporting Information). In contrast, the effect of PACAP could be observed only after 
120 minutes (Fig. 4d), suggesting that PACAP indirectly stimulates muscarinic 
receptors or produces its effects via other pathways or mechanisms affecting sweat 
gland secretion.  
 The molecular mechanisms of sweat secretion have only been partly 
elucidated. Sweating can occur when periglandular cholinergic, α-adrenergic or 
β-adrenergic nerves are activated, but cholinergic sweat secretion is considered as the 
major route and adrenergic sweating under physiological conditions is mostly 
unkonown.
34
 A previous study reported that β-adrenergic regulation is abnormal in 
cystic fibrosis sweat glands mediated by the cAMP pathway.
35
 cAMP plays a second 
messenger role in the adrenergic sweating response by activating protein kinase A 
(PKA).
1,36
 A previous study examined the ultracytochemical localization of adenylate 
cyclase in human sweat glands after stimulation with PACAP.
23
 They showed that the 
reaction product of adenylate cyclase activity was associated with apical and lateral 
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plasma membranes and with membranes of clear cells lining the intercellular canaliculi. 
In dark cells, adenylate cyclase activity was present on apical and lateral plasma 
membranes. PACAP could thus promote sweat secretion by modulating adenylate 
cyclase activity in the β-adrenergic, cAMP-mediated sweat secretion pathway. Data 
from our recent paper that showing that an adenylate cyclase inhibitor (SQ22536) 
blocked PACAP-stimulated tear secretion
22
 could support this hypothesis. Dark cells 
have relatively few mitochondria and membrane villi, and were long thought to play a 
minor role in sweat secretion.
1,34
 A recent study on the Foxa1–Best2 cascade suggests a 
more decisive involvement of dark cells in sweat secretion.
37
 PACAP as such could be 
involved in sweat secretion from dark cells. Ca
2+
 is also unequivocally required for 
sweat secretion.
38
 The immediate response to cholinergic input on eccrine glands is a 
sharp increase of cytosolic Ca
2+
. This is accomplished from two sources: influx from 
the extracellular interstitial fluid and release of Ca
2+
 from intracellular stores, the latter 
of which could be mediated, at least in part, by InsP3. When acetylcholine activates the 
Chrm3 receptor, InsP3 is produced from phosphatidylinositol 4,5-bisphosphate (PIP2) 
in the secretory cells, most likely through the action of phospholipase C (PLC) action, 
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which then promotes intracellular Ca
2+
 release from the endoplasmic reticulum.
1
 As 
PACAP could activate PLC and increase intracellular Ca
2+
,
39
 this pathway might also 
be associated with sweat secretion by PACAP. Several studies reported that 
aquaporin-5 (AQP5) is involved in fluid secretion by salivary, submucosal and eccrine 
sweat glands.
40-42
 AQP5 production through the cAMP-PKA/CREB pathway, was 
reported to influence the secretory function of the submucosal glands in nasal 
epithelium.
43
 The de novo synthesis of AQP5 protein might be involved in sweat 
secretion by PACAP. Further investigation is needed to elucidate the molecular 
mechanisms of PACAP-mediated sweat secretion.  
   Other studies have concluded that intravenous infusion of PACAP in healthy 
humans induced significant vasodilatation, flushing, and edema in a 
concentration-dependent manner via VPAC1R, which occurred after 15 minutes and 
peaked after 30 minutes.
33
 Other experiments have shown that PACAP, injected i.v. 
into the rat, evoked saliva secretion from the three major salivary glands.
44
 Considered 
in conjunction with the present research, it is reasonable to postulate that PACAP plays 
an important role in various external secretory processes and in vasodilation in the skin. 
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It is very likely that these highly variable functions are strongly influenced by the 
PACAP receptor subtypes or other trophic factors or signal transduction molecules that 
are present locally.  
   Previous studies on eccrine sweat glands suggested that VIP stimulates sweat 
secretion by elevating the cAMP concentration, and acts as a synergist for both 
acetylcholine- and β-adrenergic- agonist-mediated sweat secretion.
1
 
45,46
On the other 
hand, administration of PACAP changed the ultracytochemical localization of 
adenylate cyclase in human sweat glands,
23
 and was much more potent than VIP in 
stimulating adenylate cyclase cAMP and catecholamine secretion.
11,47
 We have 
demonstrated here that VIP administration did not significantly promote sweat secretion 
(Fig. 5). PACAP could thus play a more dominant role than VIP in eccrine sweat gland 
secretion, possibly via the cAMP pathway through PAC1R activation.  
   The localization of PACAP receptors in sweat glands and PACAP’s possible role in 
sweat secretion have not been established previously. While the secretion of sweat 
requires contraction of the myoepithelial cells surrounding secretory cells, we did not 
find strong PAC1R immunoreactivity in myoepithelial cells. Furthermore, PACAP was 
Page 25 of 53 British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
localized to nerve fibres around sweat glands and to secretory cells. Consistent with our 
results, a previous investigation showed that PACAP localized to nerve fibres around 
human sweat glands
48
. These data suggest that PACAP may not stimulate sweat 
secretion by inducing myoepithelial contraction around the secreting cells, but rather 
promote secretion itself in an autocrine manner and/or via nerve fibre projections from 
the sympathetic nervous system.  
   In summary, the local administration of PACAP to the footpads of mice promoted 
sweat secretion in a manner that may be mediated through PAC1R expressed in sweat 
gland secretory cells. Further study is needed to determine if PACAP is an essential 
mediator of sweat secretion in healthy skin or in disorders involving hyperhidrosis and 
anhidrosis, such as Sjögren’s syndrome, Fabry disease, atopic dermatitis, lichen planus 
and psoriasis. This potent peptide and its receptors may provide new therapeutic options 
or new perspectives on clinical sweating disorders.  
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Fig S1. Positive control showing PACAP antibody specificity in nerve fibres in the 
mouse brain hypothalamus. 
Fig S2. Quantitative sweat secretion data following pilocarpine administration to the 
footpads of wild type and PACAP KO mice.  
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Figure legends  
Fig 1. Expression of PACAP, VIP and their receptors in mouse footpad. The 
predicted sizes of RT-PCR products are 275 bp for PACAP, 260 bp for VIP, 326 bp for 
PAC1R, 418 bp for VPAC1R and 387 bp for VPAC2R. β-actin (302 bp) was used as a 
positive control. The expression of PACAP, VIP, PAC1R, VPAC1R and VPAC2R 
mRNAs was detected in mouse footpad. Primer sequences and PCR conditions are 
given in Table 1.  
 
Fig 2 Localization of PACAP and PAC1R in mouse footpad. (a-c) Eccrine sweat 
glands were double-immunostained with PACAP (red), neurofilament-200 (NF-200, 
green) and DAPI (blue). Most PACAP immunoreactivity was observed in nerve fibres 
around sweat glands and secretory cells. PACAP and NF-200 immunoreactivity 
frequently overlapped (arrows). Scale bar = 20 µm. (d-f) Immunohistochemical 
staining shows PAC1R expression in sweat gland cells and in the basal, polygonal and 
granular layers of the epidermis. Immunoreactivity in the stratum corneum can also be 
observed in the negative control (d). Strong PAC1R immunoreactivity is detected in 
the secretory cells of eccrine sweat glands (e, f). (d, e); scale bar = 200 µm, (f); scale 
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bar = 20 µm. (g-i) Mouse eccrine sweat gland sections were double-immunostained 
with PAC1R (red), smooth muscle actin (SMA, green) and DAPI (blue). Most 
PAC1R-positive cells are secretory cells. SMA and PAC1R immunoreactivity do not 
overlap (scale bar = 20)  
 
Fig 3. PACAP and PAC1R mRNA expression, and the localization of PAC1R 
immunoreactivity in human plantar skin. (a) PACAP and PAC1R mRNA expression 
was analyzed by RT-PCR. Equivalent amounts of cDNA from human plantar dermis 
and brain (positive control) were used. PAC1R levels in the plantar dermis were 
similar to those in brain, while levels of PACAP were lower. β-actin used as a 
housekeeping gene was detected at similar levels in the total mRNA of control brain 
and plantar dermis. Primer sequences and conditions for PCR are given in Table 1. 
(b-d) Eccrine sweat glands were double-immunostained with PACAP (red), 
neurofilament-200 (NF-200, green) and DAPI (blue). Most PACAP immunoreactivity 
was observed in nerve fibres around sweat glands and secretory cells. PACAP and 
NF-200 immunoreactivity frequently overlapped (arrows). Scale bar = 20 µm. 
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 (e) Localization of PAC1R by immunohistochemical staining in human plantar skin. 
PAC1R was mainly observed in eccrine sweat gland secretory cells (scale bar = 20 µm). 
(f-h) Human sweat gland sections were double-immunostained with PAC1R (red), 
smooth muscle actin (SMA, green) and DAPI (blue). Most PAC1R-positive cells are 
secretory cells. (scale bar = 20 µm).  
 
Fig 4. Sweat secretion response to PACAP administration in mouse footpad. (a) 
Schematic diagram for evaluating sweat secretion after PACAP injection. Immediately 
after adult C57BL/6J mice (n = 10) were anesthetized, PACAP in the amount of (0 mol, 
0.5 fmol, 50 fmol, 5 pmol) in 5 µl saline was injected subcutaneously into the footpad. 
Functional sweat secreting glands were visualized by the starch iodine test and footpad 
images were taken 60, 90 and 120 min after injection. (b) Schematic diagram showing 
protocol to assess the effect of anesthesia on sweat secretion. In this series of 
experiments, PACAP or vehicle was injected into the mouse footpad 60 min after 
anesthesia. (c) Representative photographs showing the mouse footpad prior to 
injection (left) and 120 min after vehicle or 5 pmol PACAP injection (right) according 
to the protocol in (a). Functional sweat-secreting glands appear as clusters of black dots 
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(arrows). After 120 min, black dots appeared in footpads of animals in 
PACAP-injected groups, but not in the vehicle group. (d) Quantitative data for sweat 
secretion induced using the protocol in (a). The injection of PACAP (5 pmol) caused a 
significant increase in number of active sweat glands compared to the control group 
120 min after injection (*P<0.05). Bars represent means ± SEM (n = 10 animals per 
group). (e) Quantitative data for sweat secretion induced according to the protocol in 
(b). While PACAP (5 pmol) did not increase sweat secretion 60 min after injection 
(120 min after anesthesia), a significant difference in sweat secretion was observed at 
the 90-minute time point after PACAP injection (150 min after anesthesia). Bars 
represent means ± SEM for n = 10 animals per group. Statistical analysis was 
performed using the Tukey-Kramer test: *P<0.05. (f) Comparison of sweat secretion 
on the ipsi- and contralaterally injected side. A significant increase of number of active 
sweat glands occurred only on the side of PACAP injection (*P<0.05). Bars represent 
means ± SEM for n = 10 animals per group.  
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Fig 5. Effects of PAC1R antagonist and VPAC1R-, VPAC2R-agonist on sweat 
secretion. (a) Protocols followed to evaluate the effect of PAC1R antagonist and 
VPAC1R-, VPAC2R-agonist on sweat secretion. After adult C57BL/6J mice (n = 10 
each group) were anesthetized, experiments of two subcutaneous injections (5 µl) into 
the footpad at a 10 min interval were performed under the following conditions. (i) 
After saline injection, saline was injected. (ii) After saline injection, PACAP (5 pmol) 
was injected. (iii) After PACAP6-38 (PAC1R antagonist, 50 pmol) injection, PACAP (5 
pmol) was injected. (iv) After saline injection, VIP (VPAC1R and VPAC2R agonist, 5 
pmol) was injected. Functional sweat-secreting glands were visualized by using the 
starch iodine test and images of footpads were taken 120 min and 150 min after the 
first injection. (b) Representative images showing mouse footpads with functional 
sweat-secreting glands seen as black dots. After 120 min, clusters of black dots 
(arrows) appeared in the PACAP-injected groups, but not the saline injected group. The 
PACAP-induced effect was suppressed by co-administration with PACAP6-38. VIP 
administration group did not significantly induce sweat secretion. (c) Quantitative data 
describing the above experiments. The injection of PACAP (5 pmol) induced a 
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significant increase in number of active sweat glands compared to the control group 
120 min and 150min after injection (*P<0.05) which was canceled by the 
co-administration of PACAP6-38 (**P<0.05). The administration of VIP did not 
significantly induce sweat secretion. Bars represent means ± SEM for n = 10 animals 
per group.  
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Table1 Primer combinations and conditions used for RT-PCR 
PACAP, pituitary adenylate cyclase-activating polypeptide; PAC1R, pituitary adenylate cyclase-activating polypeptide specific receptor;                                             
VPAC1R, vasoactive intestinal peptide receptor 1; VPAC2R, vasoactive intestinal peptide receptor 2  
 
Name Official symbol Species Forward (5’ to 3’) Reverse (5’ to 3’) Product size (BP) TM(°C) Cycles 
PACAP ADCYAP human GGAAACAAATGGCTGTCAAG GGATAGAACACACGAGCGATG 193 60°C -55°C  
55°C           
1 cyc each degree 
35 cyc 
PAC1R ADCYAP1R human CTCACCACTGCCATGGTCATC GCCCTCAGCATGAACGACAC 98 60°C 40 cyc 
β-actin ACTB human TGGCACCCAGCACAATGAA CTAAGTCATAGTCCGCCTAGAAGCA 186 55°C 25 cyc 
PACAP Adcyap mouse CCGAAAACAAATGGCTGTCAAG CTGTGCATTCTCTAGTGCTTCA 275 60°C 33 cyc 
VIP Vip mouse TTTGAAGGAGCAGGTGACCC ACGGCATCAGAGTGTCGTTT 260 60°C 33 cyc 
PAC1R Adcyap1r mouse GGAATGCAAAGCTGTCATGGTT GCACAAGGATGATGATGATGCC 326 60°C 33 cyc 
VPAC1R Vipr1 mouse GAAGCTGCACTGTACTCGAAAC CAAGATGGAGATGAGGATGGGG 418 60°C 35 cyc 
VPAC2R Vipr2 mouse CTAGCGATGGATGGTCAGAGAC CCACCAGAAGCCAGTAGAAGTT 387 60°C 35 cyc 
β-actin Actb mouse ACGTTGACATCCGTAAAGACCT GGTGTAAAACGCAGCTCAGTAA  302 55°C 25 cyc 
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Supplementary figure legends 
Fig S1. Positive control showing PACAP antibody specificity in immunostained nerve 
fibres in the mouse brain hypothalamus. 
 For the positive control, mouse brain sections were double-immunostained with 
PACAP (red) and anti neurofilament-200 (NF-200, green). Mouse monoclonal antibody 
against PACAP was created by J. Hannibal
1,2 (Department of Clinical Biochemistry, 
Bispebjerg Hospital, University of Copenhagen, Denmark). Immunoreactivity of 
PACAP and NF-200 often overlapped (scale bar = 100 µm). Negative control sections 
were stained without primary antibody (d-f) 
 
 
Fig S2. PACAP deficiency did not influence pilocarpine-induced sweat secretion. 
Quantitative data for sweat secretion after pilocarpine administration in wild type and 
PACAP KO mice. When pilocarpine was injected into the mouse footpad, functional 
sweat glands were observed within 5 min and remained constant thereafter. No 
significant difference between wild type and PACAP KO mice was detected in 
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pilocarpine-induced sweat secretion. Bars represent means ± SEM for n = 5 per group. 
 
Supplementary materials and methods 
Immunostaining 
Mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and perfused 
transcardially with saline, followed by 4% paraformaldehyde (PFA) in 50 mM phosphate 
buffer (pH 7.2). Footpads were removed and post-fixed in 4% PFA overnight at 4 °C. For 
PACAP immunostaining, Zamboni’s solution (2% PFA and 15% picric acid in 0.1 M 
phosphate buffer pH 7.2) was used instead of 4% PFA as described previously.
1,2
 
After immersion in 20% sucrose in 0.1 M phosphate buffer (pH 7.2) at 4 °C, the footpad 
was embedded in O.C.T. compound (Sakura Finetek, Tokyo, Japan), and frozen. Frozen 
sections were cut with a microtome at a thickness of 5 µm.  
   Experimental human tissues were embedded in O.C.T. compound (Sakura Finetek) 
and frozen in liquid nitrogen. Frozen sections were cut with a microtome at a thickness of 
5 µm. Human samples were post-fixed in 4% PFA for 30 minutes (for PACAP staining, 
in Zamboni’s solution overnight at 4 °C) before immunostaining.  
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Single immunostaining; microscope slides with tissue sections were washed with 
phosphate-buffered saline (PBS, pH7.2). The sections were then placed into citrate (10 
mM, pH6.0) at 85 °C for 20 minutes. After treatment with 0.3 % H2O2 in PBS to quench 
endogenous peroxidase, the sections were placed in 5 % normal horse serum (NHS) in 
PBS to block nonspecific binding for 60 minutes. The sections were incubated overnight 
with rabbit anti-PAC1R polyclonal antibody (1:400; produced in our laboratory) at 4 °C, 
washed with PBS and further incubated with biotinylated goat anti-rabbit IgG (1:200; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 hours at room temperature, 
followed by reaction with an avidin-biotin complex solution (Vector, Burlingame, CA, 
USA) and then diaminobenzidine (Vector) as a chromogen. The nuclei were 
counterstained with hematoxylin. Single immunostaining was detected using an AX70 
microscope (Olympus, Tokyo, Japan). 
   Double immunostaining; sections were washed with PBS (pH7.2), then placed into 
citrate (10 mM, pH6.0) at 85 °C for 20 minutes. After treatment, the sections were placed 
in 5 % NHS in PBS for 60 minutes. For PACAP staining, the sections were placed in 5 % 
NHS in 0.3 % Triton X-100 for 60 minutes, incubated overnight with rabbit anti-PAC1R 
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polyclonal antibody (1:400; prepared in our laboratory), mouse anti-Smooth Muscle 
Actin (SMA) monoclonal antibody (1:400; R & D SYSTEMS, Cat.: MAB1420, 
Minneapolis, MN), mouse monoclonal antibody directed against PACAP (code Mab 
JHH1, diluted 1:5; created by Jens Hannibal, Department of Clinical Biochemistry, 
Bispebjerg Hospital, University of Copenhagen, Denmark)
1,2
 and rabbit 
anti-neurofilament 200 (NF-200) polyclonal antibody (1:5000; SIGMA, Pro.: N 4142, 
Saint Louis, MO) as primary antibodies. The sections were then rinsed with PBS and 
visualized with Alexa546 anti-rabbit IgG antibody (1:400; Life Technologies, Carlsbad, 
CA), Alexa Fluor488 anti-mouse IgG (1:400; Life Technologies), Alexa546 anti-mouse 
IgG antibody (1:400; Life Technologies) and Alexa Fluor488 anti-rabbit IgG (1:400; Life 
Technologies). The specificity of PACAP antibody in nerve fibers was confirmed in 
immunostained mouse brain hypothalamus (Fig. S1). Sections were counterstained with 
4,6-Diamidine-2-phenylindole dihydrochloride (DAPI, 1:10000; Roche, Mannheim, 
Germany,) to identify cell nuclei. ApoTome (Zeiss, Oberkochen, Germany) (Figs 4c-e) 
and Nikon A1 confocal microscopy (Nikon, Tokyo, Japan) (Figs 5c-e and Figs 6) were 
used for acquiring images. 
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Experimental PACAP-deficient animals  
The properties of PACAP-deficient mice have been reported previously.
3
 Experiments 
were carried out using littermates (Wild type, PACAP +/+; KO, PACAP -/-) from the 
breeding of PACAP heterozygous KO mice (PACAP +/-). 
 
Evaluation of sweat secretion by pilocarpine-injected mice  
Functional sweat-secreting glands were visualized by the Wada-Takagaki method. After 
wild-type (n=5) and PACAP KO mice (n=5) had been anesthetized with 10 µl/g B.W. 
pentobarbital (Kyoritsu, Tokyo, Japan), pilocarpine (50 µg in 5 µl saline; a non-selective 
muscarinic receptor agonist, SIGMA ALDRICH, St. Louis, MO) was subcutaneously 
injected into the footpad. Images were taken 5, 10 and 15 min after pilocarpine injection 
and black dots which appeared as a consequence of sweat reaction were counted for 
quantification. 
 
Supplementary References 
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